<DOC>
	<DOCNO>NCT02949076</DOCNO>
	<brief_summary>Cancer treatment profound effect skeletal muscle , well-recognized atrophy , weakness diminish oxidative capacity . These adaptation negatively impact quality life , treatment decision survival . Despite consequence , factor promote adaptation remain poorly define understudied human patient . To address gap knowledge , goal study examine role muscle disuse regulator muscle size function human cancer patient</brief_summary>
	<brief_title>Skeletal Muscle Atrophy Dysfunction Human Cancer</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>5075 yrs age histologicallydocumented , stage III IV nonsmall cell lung carcinoma ( NSCLC ) estimate life expectancy &gt; 6 mo Karnofsky 's performance score â‰¥70 history , sign symptoms inflammatory autoimmune disease uncontrolled hypertension heart renal failure exercise limitation peripheral vascular disease stroke neuromuscular disease knee/hip replacement additional , activelytreated malignancy history malignancy , except nonmelanoma skin cancer take medication anticoagulant effect stop prior muscle biopsy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>